News
By Stephanie Brown HealthDay ReporterTUESDAY, June 3, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...
The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...
The new vaccine is indicated for individuals who have been previously vaccinated with any COVID-19 vaccine and are 65 years or older, or 12 to 64 years of age with at least 1 underlying condition that ...
Moderna announced this weekend that the Food and Drug Administration approved its lower-dose Covid-19 vaccine for adults 65 ...
A Phase III trial demonstrated mNEXSPIKE’s non-inferior efficacy compared with Moderna’s original COVID vaccine, Spikevax.
FDA approves Moderna’s mNEXSPIKE COVID-19 vaccine for high-risk groups Phase 3 trial shows mNEXSPIKE outperforms original ...
Moderna, over the weekend, announced that the U.S. Food and Drug Administration had approved its second-generation COVID ...
The Food and Drug Administration has approved Moderna's new COVID-19 vaccine, days after the federal government tightened ...
5don MSN
Rep. Marjorie Taylor Greene slams FDA green lighting of Moderna's mNEXSPIKE COVID-19 vaccine, describing the move as "Not ...
The Food and Drug Administration approved Moderna's next-generation COVID-19 vaccine for adults 65 and older, the company ...
Moderna's mNexspike COVID vaccine approved by FDA for older adults and at-risk groups after Phase 3 trial shows improved ...
The Food and Drug administration has approved a new COVID-19 vaccine made by Moderna but with limits on who can use it.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results